|Bid||22.00 x 800|
|Ask||22.61 x 1100|
|Day's range||20.07 - 22.02|
|52-week range||12.65 - 35.36|
|Beta (5Y monthly)||1.01|
|PE ratio (TTM)||N/A|
|Earnings date||22 Feb 2023 - 27 Feb 2023|
|Forward dividend & yield||N/A (N/A)|
|1y target est||36.20|
Relay Therapeutics, Inc. (RLAY) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
CAMBRIDGE, Mass., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, is scheduled to present at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023 at 2:15 p.m. PT. The presentation will be webcast live and may be accessed through Relay Therapeutics’ website under Events in the News & Events s
Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Relay Therapeutics...